VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ZYXI
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ZYXIZynex, Inc.
$0.06$2M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksZYXIFinancials

Zynex, Inc. (ZYXI) Financials

26Y historyFree accessUpdated daily

Revenue plummeted to $13.4 million in 2025Q3, representing a 73.3% year-over-year contraction while gross margins compressed to 60.5% from historical 80% levels.

ZYXI Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'98
Sales/Revenue108.2M192.35M184.32M158.17M130.3M80.12M45.47M31.92M23.43M13.31M11.64M11.12M21.68M39.67M34.15M24.09M18.68M11.76M8.05M2.56M2.26M1.26M000160.88K12.41K
Revenue Growth %-44.13%4.36%16.54%21.39%62.63%76.2%42.47%36.21%76.01%14.36%4.71%-48.73%-45.33%16.16%41.78%28.93%58.81%46.16%214.78%13.19%79.74%----100%1195.98%-
Cost of Goods Sold30.69M39.43M38.37M32.01M26.92M17.42M8.81M6.04M4.82M3.52M4.94M7.61M8.14M8.77M7.37M5.2M3.79M2.24M729.05K303.72K309.63K237.64K000232.37K6.21K
COGS % of Revenue-20.5%20.81%20.23%20.66%21.74%19.38%18.92%20.57%26.42%42.41%68.47%37.54%22.11%21.59%21.6%20.31%19.04%9.06%11.88%13.71%18.91%---144.43%50%
Gross Profit77.51M152.93M145.96M126.16M103.38M62.7M36.66M25.88M18.61M9.8M6.7M3.5M13.54M30.9M26.78M18.88M14.89M9.52M7.32M2.25M1.95M1.02M000-71.49K6.21K
Gross Margin %71.64%79.5%79.19%79.77%79.34%78.26%80.62%81.08%79.43%73.58%57.59%31.53%62.46%77.89%78.41%78.4%79.69%80.96%90.94%88.12%86.29%81.09%----44.43%50%
Gross Profit Growth %-4.77%15.69%22.04%64.87%71.05%41.65%39.04%90.01%46.12%91.27%-74.12%-56.16%15.38%41.8%26.83%56.32%30.12%224.85%15.59%91.28%---100%-1251.7%-
Operating Expenses145.42M146.94M135.18M103.22M81.01M52.46M25.59M15.51M9.67M9.16M9.19M9.2M21.14M28.16M23.68M17.32M11.07M9.21M4.16M2.42M1.94M1.99M35.52K22.72K37.35K1.53M17.55K
OpEx % of Revenue-76.39%73.34%65.26%62.17%65.47%56.28%48.59%41.26%68.77%78.9%82.77%97.51%70.99%69.33%71.92%59.28%78.33%51.65%94.68%86.01%158.18%---948.75%141.36%
Selling, General & Admin114.68M146.94M135.18M103.22M77.46M52.46M25.59M15.51M9.67M9.16M9.19M11.4M21.14M18.04M23.68M17.32M11.07M9.21M4M2.33M1.88M1.91M35.52K22.72K37.35K1.51M17.18K
SG&A % of Revenue-76.39%73.34%65.26%59.45%65.47%56.28%48.59%41.26%68.77%78.9%102.52%97.51%45.48%69.33%71.92%59.28%78.33%49.74%91%83.14%151.82%---940.51%138.42%
Research & Development12M0002.6M0600K200K100K256K256K394K754K874K0000000000000
R&D % of Revenue----2%-1.32%0.63%0.43%1.92%2.2%3.54%3.48%2.2%-------------
Other Operating Expenses0000949K0880K00-204K-7K-47K77K31K0000153.44K94.01K64.8K80.03K00013.26K366
Operating Income-67.91M5.99M10.78M22.94M22.37M10.25M11.07M10.37M8.94M640K-2.48M-5.7M-7.6M2.74M3.1M1.56M3.81M309.18K3.16M-167.71K6.41K-968.83K-35.52K-22.72K-37.35K-1.6M-11.34K
Operating Margin %-62.76%3.11%5.85%14.5%17.16%12.79%24.34%32.49%38.17%4.81%-21.31%-51.25%-35.05%6.9%9.08%6.48%20.42%2.63%39.29%-6.56%0.28%-77.09%----993.41%-91.36%
Operating Income Growth %--44.43%-53%2.56%118.23%-7.38%6.71%15.94%1297.5%125.8%56.45%25.04%-377.68%-11.74%98.65%-59.07%1133.54%-90.22%1985.57%-2717.23%100.66%-2627.47%-56.34%39.18%97.66%-13991.19%-
EBITDA-64.31M10.77M15M26.07M24.65M11.82M11.84M10.82M9.23M1.07M-2.06M-5.04M-6.76M3.65M3.91M2.33M4.49M745.67K3.53M77.32K71.21K-924.04K-35.52K-22.72K-37.35K-1.58M-10.98K
EBITDA Margin %-59.44%5.6%8.14%16.48%18.92%14.75%26.05%33.89%39.39%8.07%-17.67%-45.31%-31.18%9.2%11.44%9.69%24.04%6.34%43.89%3.02%3.15%-73.53%----984.94%-88.42%
EBITDA Growth %-580.71%-28.19%-42.45%5.73%108.54%-0.19%9.48%17.2%758.6%152.26%59.16%25.5%-285.28%-6.6%67.32%-48.01%502.31%-78.89%4469.02%8.58%107.71%-2501.4%-56.34%39.18%97.64%-14336.97%-
D&A (Non-Cash Add-back)3.6M4.78M4.22M3.13M2.29M1.57M778K448K286K435K424K660K839K912K806K774K677.41K436.49K370.25K245.03K64.8K44.78K00013.62K366
EBIT-67.91M6.01M13.67M22.64M22.37M10.17M11.07M10.37M8.94M640K-2.49M-5.74M-7.52M2.77M3.1M1.55M3.99M336.57K3.17M-167.71K232.22K-968.83K108.03K72.03K0-1.6M-10.99K
Net Interest Income-3.04M-2.38M-1.09M-440K-95K-19K-5K-154K-1.45M-352K-503K-536K-607K-435K-459K-210K-161K-65.2K-244.82K-154.12K-37.09K-37.38K-110.1K000-5.5K
Interest Income000000000000001K5K4.13K424241.37K2341.36K0000352
Interest Expense3.04M2.38M1.09M440K95K19K5K154K1.45M352K503K536K607K435K460K215K164.99K65.62K244.84K155.49K37.32K38.74K110.1K72.03K91.42K30.29K5.85K
Other Income/Expense-3.04M-2.36M1.8M-740K-95K-96K875K-154K-1.45M-556K-510K-583K-530K-401K-457K-226K9.49K-38.22K-240.98K-152.66K101.55K-39.89K35.52K-72.03K-91.42K-30.29K-5.5K
Pretax Income-70.95M3.63M12.58M22.2M22.27M10.15M11.94M10.22M7.49M84K-2.99M-6.28M-8.13M2.34M2.64M1.33M3.82M270.95K2.92M-320.37K107.96K-1.01M-145.62K-94.75K-128.77K-1.63M-16.84K
Pretax Margin %-65.57%1.89%6.82%14.03%17.09%12.67%26.26%32.01%31.98%0.63%-25.69%-56.49%-37.49%5.89%7.74%5.54%20.47%2.3%36.3%-12.53%4.78%-80.27%----1012.24%-135.65%
Income Tax3.01M633K2.85M5.15M5.17M1.08M2.45M664K129K15K-57K-49K-790K788K1.08M985K1.44M160K790K0-101.55K-32.84K145.62K0000
Effective Tax Rate %-4.24%17.45%22.63%23.2%23.21%10.63%20.51%6.5%1.72%17.86%1.91%0.78%9.72%33.73%40.85%73.78%37.69%59.05%27.04%0%-94.06%3.26%-100%0%0%0%0%
Net Income-73.96M2.99M9.73M17.05M17.1M9.07M9.49M9.55M7.37M69K-2.91M-6.2M-7.3M1.55M1.56M350K2.38M110.95K2.13M-320.37K107.96K-975.88K-145.62K-94.75K-128.77K-1.63M-16.84K
Net Margin %-68.35%1.56%5.28%10.78%13.13%11.33%20.87%29.93%31.43%0.52%-25.01%-55.76%-33.67%3.92%4.58%1.45%12.75%0.94%26.48%-12.53%4.78%-77.66%----1012.24%-135.65%
Net Income Growth %-1633.13%-69.24%-42.91%-0.32%88.48%-4.4%-0.63%29.69%10573.91%102.37%53.04%15.09%-570.12%-0.7%346.86%-85.31%2047.16%-94.79%765.28%-396.76%111.06%-570.16%-53.68%26.42%92.09%-9570.52%-
Net Income (Continuing)-73.96M2.99M9.73M17.05M17.1M9.07M9.49M9.55M7.37M69K-2.93M-6.23M-7.34M1.55M1.56M350K2.38M110.95K2.13M-320.37K301.06K-975.88K40.7K-94.75K-128.77K-1.63M-16.84K
Discontinued Operations000000000000000000000000000
Minority Interest000000-89K-89K-89K-89K-89K-66K-34K5K0000000000000
EPS (Diluted)-2.440.090.270.440.400.240.250.260.200.00-0.08-0.18-0.210.050.050.010.070.000.06-0.010.01-0.04-0.01-0.64-81.97-682.53-0.00
EPS Growth %-1741.28%-66.67%-38.64%10%66.67%-4%-3.85%30%-102.36%53%14.29%-561.54%0%--87.48%--94.81%625.62%-123.33%-99.06%99.22%87.99%--
EPS (Basic)-0.090.270.440.410.240.270.270.210.00-0.08-0.18-0.210.050.050.010.070.000.07-0.010.01-0.04-0.01-0.64-81.97-682.53-0.00
Diluted Shares Outstanding30.31M32.3M36.14M39.13M43.12M38.44M37.36M37.45M36.52M34.4M34.4M34.33M34.27M34.34M34.08M33.78M33.41M33.69M31.3M26.43M25.43M25M24.37M148.53K1.57K2.39K37.45M
Basic Shares Outstanding30.31M31.94M35.55M38.47M42.15M37.26M35.68M35.75M35.37M34.4M34.4M34.1M34.27M34.17M33.83M33.6M33.13M31.89M29.26M26.43M25.43M25M24.37M148.53K1.57K2.39K35.75M
Dividend Payout Ratio-0.3%0.03%21.19%0.01%-23.83%--------------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Severe Revenue and Margin Erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2025Q3)

Sharp Revenue Contraction Trends Observed

As reported in recent financial statements, ZYXI experienced a dramatic revenue decline to $13.4 million in 2025Q3, representing a 73.3% year-over-year contraction that signals significant instability in the company's core outpatient electrotherapy business model and its ability to maintain historical prescription volumes.

The precipitous drop in quarterly revenue suggests that the company's reliance on a direct sales force may no longer be effectively converting physician interest into billable insurance claims. Investors should monitor whether this trend reflects a fundamental loss of market share or a broader regulatory tightening of medical necessity requirements for electrotherapy devices.

Gross Margin Compression Warrants Caution

Based on the company's latest quarterly filings, gross margins have deteriorated to 60.5% in 2025Q3, a significant departure from the 80% levels maintained throughout 2023 and early 2024, indicating potential pricing pressure or a shift toward lower-reimbursing payer segments within the US market.

The erosion of gross margin suggests that the company's high-margin 'razor-blade' model for consumables is facing structural headwinds. This contraction may imply that the company is forced to accept lower reimbursement rates to maintain volume, which undermines the long-term profitability of its installed base.

Operating Leverage Turns Deeply Negative

According to the income statement data, ZYXI's operating income plummeted to a loss of $44.0 million in 2025Q3, as SG&A expenses of $21.3 million failed to scale down in proportion to the collapsing top-line revenue, resulting in a negative operating margin of 3.3%.

The inability to right-size SG&A expenses in response to falling revenue indicates a lack of operational flexibility. This suggests that the company's fixed cost base, particularly its sales infrastructure, has become a significant burden that is actively accelerating the depletion of capital reserves.

Sustainability of Current Business Model

Financial data indicates that ZYXI's net income has swung to a $42.9 million loss in 2025Q3, raising serious questions about the viability of the current business model as the company struggles to reconcile high fixed operating costs with a rapidly shrinking revenue base.

Short-sellers would likely focus on the disconnect between the company's historical reliance on aggressive sales expansion and the current reality of declining demand. The transition to negative net margins suggests that the company may be approaching a critical inflection point where external financing or drastic restructuring becomes necessary.

ZYXI — Frequently Asked Questions

Quick answers to the most common questions about buying ZYXI stock.

What was Zynex, Inc.'s (ZYXI) revenue in 2024?

For fiscal year 2024, Zynex, Inc. (ZYXI) reported total revenue of $192.4M. This represents a 1549392.5% increase compared to $0.0M in 1998.

Is Zynex, Inc. (ZYXI) profitable?

Zynex, Inc. (ZYXI) is profitable, generating $3.0M in net income for the fiscal year ending 2024 with a net profit margin of 1.6%.

What is Zynex, Inc.'s operating profit margin?

Zynex, Inc. (ZYXI) reported an operating income of $6.0M, resulting in an operating profit margin of 3.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Zynex, Inc.'s gross profit and gross margin?

Zynex, Inc. (ZYXI) generated $152.9M in gross profit for the year, representing a gross profit margin of 79.5%. This demonstrates the company's core pricing power and production efficiency.